Deflazacort dose optimization and safety evaluation in Duchenne muscular dystrophy (DOSE): A randomized, double-blind non-inferiority trial.

Abstract

US food and drug administration has recently approved deflazacort for Duchenne muscular dystrophy (DMD) and recommended the dosage of 0.9mg/kg/d for patients aged ≥5years. However, data assessing the minimal efficacious dose and need of dose-titration based on age or disease severity is limited. To determine whether deflazacort 0.45mg/kg/d (proposed lower dosage) is non-inferior to 0.9mg/kg/d among newly diagnosed patients with DMD. A double-blinded, non-inferiority, randomized trial, conducted between December 2018 and July 2020. Newly diagnosed patient aged 5-15 years with genetic or muscle biopsy confirmed DMD and baseline 6-min walk distance (6MWD)>150m were screened. Patients were randomly assigned (1:1), stratified to prespecified subgroups by age (≤7years and >7years), and baseline 6MWD (≤350m and >350m), to receive either 0.45mg/kg/d or 0.9mg/kg/d regimens. The primary endpoint was the change in 6MWD, from baseline to week-24 of intervention. The trial was powered with a predefined, non-inferiority margin of 30m. The analyses were by modified intention-to-treat (mITT). A total of 97 patients were enrolled, 40 receiving 0.45mg/kg/d and 45 receiving 0.9mg/kg/d deflazacort comprised of mITT population. For primary endpoint analysis the mean (SD) change in 6MWD from baseline to week-24 was 9.7m (41.5) in deflazacort 0.45mg/kg/d, and 34.7m (43.5) for 0.9mg/kg/d. The mean difference in change in 6MWD across the group was 24.8m (95% CI 6.7 to 43, p value 0.008). The mean difference in change in 6MWD in the subgroups of boys ≤7 years of age was 21.8m (95% CI -0.82, 44.5, p=0.059), with baseline 6MWD of >350m was 19.9m (95% CI -2.4, 42.4; p=0.08). The incidence of combined moderate to severe treatment-related adverse events was significant in the 0.9mg/kg/d group by week 24 (odds ratio 0.36 [95% CI, 0.14 to 0.89], p=0.03). The efficacy of proposed low dose deflazacort in comparison to the standard dose did not meet the prespecified criteria for non-inferiority. The low dose deflazacort was non-inferior in subgroup of patients with age ≤7 years and baseline 6MWD of >350m. Clinical Trial Registry-India Identifier: CTRI/2019/02/017388.